Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study...
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions,...
Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects to complete enrollment and data collection by the end...
Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building...
Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach...
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability,...
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver...
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...